Barostim treatment adoption grows with Baylor Scott & White Health partnership

Barostim treatment adoption grows with Baylor Scott & White Health partnership
CVRx and Baylor expand Barostim

CVRx announced that Baylor Scott & White Health is continuing to expand patient access to Barostim for individuals living with heart failure.

The update highlights a partnership with Baylor Scott & White Medical Center and several clinicians. This development marks a further rollout of CVRx’s Barostim therapy in a key U.S. healthcare system, reflecting growing adoption and clinical use.

CVRx recently backed Endeavor Health’s first Barostim procedure to expand treatment options for heart failure patients, as reported in a previous article. The company also supported the first Barostim implant at Glens Falls Hospital, bringing the device to local patients, according to earlier coverage. These initiatives mark additional steps in Barostim’s rollout to U.S. healthcare systems.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.